Literature DB >> 28179278

Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation.

Roberto Avellino1, Ruud Delwel1.   

Abstract

One of the most studied transcription factors in hematopoiesis is the leucine zipper CCAAT-enhancer binding protein α (C/EBPα), which is mainly involved in cell fate decisions for myeloid differentiation. Its involvement in acute myeloid leukemia (AML) is diverse, with patients frequently exhibiting mutations, deregulation of gene expression, or alterations in the function of C/EBPα. In this review, we emphasize the importance of C/EBPα for neutrophil maturation, its role in myeloid priming of hematopoietic stem and progenitor cells, and its indispensable requirement for AML development. We discuss that mutations in the open reading frame of CEBPA lead to an altered C/EBPα function, affecting the expression of downstream genes and consequently deregulating myelopoiesis. The emerging transcriptional mechanisms of CEBPA are discussed based on recent studies. Novel insights on how these mechanisms may be deregulated by oncoproteins or mutations/variants in CEBPA enhancers are suggested in principal to reveal novel mechanisms of how CEBPA is deregulated at the transcriptional level.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28179278     DOI: 10.1182/blood-2016-09-687822

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Introduction to the review series on transcription factors in hematopoiesis and hematologic disease.

Authors:  David M Bodine
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

2.  Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice.

Authors:  Ayumi Hashimoto; Chan Gao; Jerome Mastio; Andrew Kossenkov; Scott I Abrams; Ashok V Purandare; Heshani Desilva; Susan Wee; John Hunt; Maria Jure-Kunkel; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2018-08-23       Impact factor: 12.701

Review 3.  The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Authors:  Naranie Shanmuganathan; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

4.  Clinical significance of BECLIN1 and ATG5 expression in acute myeloid leukemia patients.

Authors:  Yun Lian; Yue Xie; Ming Hong; Yu Zhu; Huihui Zhao; Xiaoli Zhao; Han Zhu; Chun Qiao; Jianyong Li; Sixuan Qian
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

5.  Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis.

Authors:  Gabriella Galatà; Andrés C García-Montero; Thomas Kristensen; Ahmed A Z Dawoud; Javier I Muñoz-González; Manja Meggendorfer; Paola Guglielmelli; Yvette Hoade; Ivan Alvarez-Twose; Christian Gieger; Konstantin Strauch; Luigi Ferrucci; Toshiko Tanaka; Stefania Bandinelli; Theresia M Schnurr; Torsten Haferlach; Sigurd Broesby-Olsen; Hanne Vestergaard; Michael Boe Møller; Carsten Bindslev-Jensen; Alessandro M Vannucchi; Alberto Orfao; Deepti Radia; Andreas Reiter; Andrew J Chase; Nicholas C P Cross; William J Tapper
Journal:  Am J Hum Genet       Date:  2021-01-08       Impact factor: 11.025

6.  Zinc Finger Protein 521 Regulates Early Hematopoiesis through Cell-Extrinsic Mechanisms in the Bone Marrow Microenvironment.

Authors:  Courtney J Fleenor; Tessa Arends; Hong Lei; Josefine Åhsberg; Kazuki Okuyama; Jacob Kuruvilla; Susana Cristobal; Jennifer L Rabe; Ahwan Pandey; Thomas Danhorn; Desiree Straign; Joaquin M Espinosa; Søren Warming; Eric M Pietras; Mikael Sigvardsson; James R Hagman
Journal:  Mol Cell Biol       Date:  2018-08-15       Impact factor: 4.272

Review 7.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 8.  Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Leonidas Benetatos; George Vartholomatos
Journal:  Cell Mol Life Sci       Date:  2018-02-26       Impact factor: 9.261

9.  Epigenetic and Epitranscriptomic Factors Make a Mark on Hematopoietic Stem Cell Development.

Authors:  Dionna M Kasper; Stefania Nicoli
Journal:  Curr Stem Cell Rep       Date:  2018-02-03

10.  The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment.

Authors:  Suchismita Daw; Sujata Law
Journal:  Mol Cell Biochem       Date:  2020-10-04       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.